MixNMatch COVID Booster Study - A Phase 1/2 Study of Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) after Receipt of EUA Vaccines (NIH / DMID)

Brief description of study

This study is called MixNMatch because its purpose is to learn about the safety, side effects, and immune response of mixing (heterologous) or matching (homologous) booster COVID-19 vaccines. All of the current vaccines in advanced development stages or approved under EUA deliver the spike protein (the protein that allows the virus to enter human cells) to the immune system to generate immunity to that specific viral protein. However, the spike protein was designed based on the virus from early 2020, and the spike continues to change with ongoing circulation of the virus. These changes lead to new strains, also called variants. Additionally, the vaccines use different vaccine platforms to deliver the spike protein. Booster vaccines using updated spike proteins to reflect the circulating variants, or using different vaccine delivery types, may improve the immune response to prevent infection longer, more effectively, or against new variants. This study uses vaccines that have received EUA approval and also vaccines that are still under investigation. If you are interested in participating in the study, please email nyuvaccinecenter@nyulangone.org .

Clinical Study Identifier: s21-00649
ClinicalTrials.gov Identifier: NCT04889209

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.